Search Clinical Trials
585,889 trials
ID
Status
Phase
Title
Sponsor
NCT07603700
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary EmbolismNanjing First Hospital, Nanjing Medical UniversityNot Yet Recruiting
NCT07603700Not Yet Recruiting
—
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonar...Nanjing First Hospital, N...
NCT07604207
Multi-organ Imaging of Microvascular and Metabolic FunctionMassachusetts General HospitalNot Yet RecruitingEarly Phase 1
NCT07604207Not Yet Recruiting
Early Phase 1
Multi-organ Imaging of Microvascular and Metabolic FunctionMassachusetts General Hos...
NCT07603245
Multidimensional Sleep Health Intervention for CouplesColumbia UniversityNot Yet RecruitingNot Applicable
NCT07603245Not Yet Recruiting
Not Applicable
Multidimensional Sleep Health Intervention for CouplesColumbia University
NCT07605312
AI-Based Risk Prediction Model for Upper Digestive Tract CancerNational Taiwan University HospitalNot Yet Recruiting
NCT07605312Not Yet Recruiting
—
AI-Based Risk Prediction Model for Upper Digestive Tract CancerNational Taiwan Universit...
NCT07604103
Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza VaccinationUniversity of BrawijayaRecruitingPhase 3
NCT07604103Recruiting
Phase 3
Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomed...University of Brawijaya
NCT07604324
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic DermatitisNovartis PharmaceuticalsNot Yet RecruitingPhase 1
NCT07604324Not Yet Recruiting
Phase 1
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Voluntee...Novartis Pharmaceuticals
NCT07604415
Active Versus Passive Anal Sphincter Training in Patients With Fecal IncontinenceComenius UniversityRecruitingNot Applicable
NCT07604415Recruiting
Not Applicable
Active Versus Passive Anal Sphincter Training in Patients With Fecal Incontinenc...Comenius University
NCT07600853
Development and Validation of an E-learning Module on Systemic Anticancer Therapy and Its Effectiveness on the Knowledge Attitude and Practice of Nurses in Administering Systemic Anticancer Agents at a Specialized Cancer Centres in Oman.Sultan Qaboos Comprehensive Cancer CenterNot Yet RecruitingNot Applicable
NCT07600853Not Yet Recruiting
Not Applicable
Development and Validation of an E-learning Module on Systemic Anticancer Therap...Sultan Qaboos Comprehensi...
NCT07603843
Use of Cognitive Aid Methods in the Management of Status EpilepticusAnkara UniversityNot Yet RecruitingNot Applicable
NCT07603843Not Yet Recruiting
Not Applicable
Use of Cognitive Aid Methods in the Management of Status EpilepticusAnkara University
NCT07605182
Effectiveness of Live Motile Sperm Sorting Device on IVF Outcomes in Advanced Paternal AgeAndrology and Fertility Hospital of HanoiNot Yet RecruitingNot Applicable
NCT07605182Not Yet Recruiting
Not Applicable
Effectiveness of Live Motile Sperm Sorting Device on IVF Outcomes in Advanced Pa...Andrology and Fertility H...
NCT07602049
Cryoablation Plus Camrelizumab for Advanced Soft Tissue SarcomaSun Yat-sen UniversityRecruitingPhase 2
NCT07602049Recruiting
Phase 2
Cryoablation Plus Camrelizumab for Advanced Soft Tissue SarcomaSun Yat-sen University
NCT07603310
Influence of Lung Recruitment Potential on PEEP Titration Strategies in ARDS Patients.Hospital Dr. Franco Ravera ZuninoNot Yet RecruitingNot Applicable
NCT07603310Not Yet Recruiting
Not Applicable
Influence of Lung Recruitment Potential on PEEP Titration Strategies in ARDS Pat...Hospital Dr. Franco Raver...
NCT07601672
PRISTINE Trial: PRoton Beam Therapy In Seminoma - Toxicity INvestigation and Evaluation of OutcomeAIRC (Italian Association for Cancer Research)Not Yet RecruitingNot Applicable
NCT07601672Not Yet Recruiting
Not Applicable
PRISTINE Trial: PRoton Beam Therapy In Seminoma - Toxicity INvestigation and Eva...AIRC (Italian Association...
NCT07601126
Respiratory Pathogen Distribution During and After the COVID-19 PandemicHisar Intercontinental HospitalCompleted
NCT07601126Completed
—
Respiratory Pathogen Distribution During and After the COVID-19 PandemicHisar Intercontinental Ho...
NCT07604766
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaGenmabNot Yet RecruitingPhase 3
NCT07604766Not Yet Recruiting
Phase 3
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Inv...Genmab
NCT07601113
PG2 Breast Cancer Evaluation in Adjuvant Medicine-Survival StudyKun-Ming RauNot Yet Recruiting
NCT07601113Not Yet Recruiting
—
PG2 Breast Cancer Evaluation in Adjuvant Medicine-Survival StudyKun-Ming Rau
NCT07602036
Type 2 Diabetes and Pregnancy a Single-arm Interventional StudyMedtronicNot Yet RecruitingNot Applicable
NCT07602036Not Yet Recruiting
Not Applicable
Type 2 Diabetes and Pregnancy a Single-arm Interventional StudyMedtronic
NCT07605091
RELIANCE: Moringa in Lactation and Early ChildhoodPhilip KernNot Yet RecruitingNot Applicable
NCT07605091Not Yet Recruiting
Not Applicable
RELIANCE: Moringa in Lactation and Early ChildhoodPhilip Kern
NCT07602699
Multi-Site Trial of Tirzepatide for Smoking CessationNational Institute on Drug Abuse (NIDA)RecruitingPhase 2
NCT07602699Recruiting
Phase 2
Multi-Site Trial of Tirzepatide for Smoking CessationNational Institute on Dru...
NCT07601451
Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment at the Center for the Study and Preservation of Eggs and Sperm: MaPreservFertiHospices Civils de LyonNot Yet Recruiting
NCT07601451Not Yet Recruiting
—
Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment...Hospices Civils de Lyon
Result Breakdown
Not yet recruiting15 (75%)
Recruiting4 (20%)
Completed1 (5%)
not_applicable9 (45%)
Not Specified5 (25%)
Phase 32 (10%)
Phase 22 (10%)
Early Phase 11 (5%)
Phase 11 (5%)